A new perspective on the potential application of RIPK1 in the treatment of sepsis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

Reference

• 1. Rudd KE, Johnson SC, Agesa KM et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet 395(10219), 200–211 (2020).
  MedlineGoogle Scholar
• 2. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315(8), 801–810 (2016). •• Describes the definition and content of sepsis (third edition).
  Medline CASGoogle Scholar
• 3. Ko BS, Choi SH, Shin TG et al. Impact of 1-hour bundle achievement in septic shock. J. Clin. Med. 10(3), 527 (2021).
  MedlineGoogle Scholar
• 4. Nedeva C, Menassa J, Puthalakath H. Sepsis: inflammation is a necessary evil. Front. Cell Dev. Biol. 7, 108 (2019).
  MedlineGoogle Scholar
• 5. Sendler M, Van Den Brandt C, Glaubitz J et al. NLRP3 inflammasome regulates development of systemic inflammatory response and compensatory anti-inflammatory response syndromes in mice with acute pancreatitis. Gastroenterology 158(1), 253–269 e214 (2020).
  Medline CASGoogle Scholar
• 6. Rovas A, Seidel LM, Vink H et al. Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis. Crit. Care 23(1), 260 (2019).
  MedlineGoogle Scholar
• 7. Kumar V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front. Immunol. 11, 1722 (2020).
  Medline CASGoogle Scholar
• 8. Yadav H, Cartin-Ceba R. Balance between hyperinflammation and immunosuppression in sepsis. Semin. Respir. Crit. Care Med. 37(1), 42–50 (2016). •• Describes the different immune states of sepsis.
  MedlineGoogle Scholar
• 9. Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat. Rev. Drug Discov. 19(8), 553–571 (2020). •• Describes the current status and trends in RIPK1 clinical research.
  Medline CASGoogle Scholar
• 10. Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat. Rev. Neurosci. 20(1), 19–33 (2019).
  Medline CASGoogle Scholar
• 11. Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc. Natl Acad. Sci. USA 116(20), 9714–9722 (2019).
  Medline CASGoogle Scholar
• 12. Degterev A, Hitomi J, Germscheid M et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4(5), 313–321 (2008). • Describes RIPK1 as a target for regulating programmed necrosis.
  Medline CASGoogle Scholar
• 13. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ. 20(2), 366 (2013).
  Medline CASGoogle Scholar
• 14. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 15(22), 6189–6196 (1996).
  Medline CASGoogle Scholar
• 15. Christofferson DE, Li Y, Hitomi J et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis. 3, e320 (2012).
  Medline CASGoogle Scholar
• 16. Holler N, Zaru R, Micheau O et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1(6), 489–495 (2000).
  Medline CASGoogle Scholar
• 17. Degterev A, Huang Z, Boyce M et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1(2), 112–119 (2005).
  Medline CASGoogle Scholar
• 18. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4), 693–703 (2008).
  Medline CASGoogle Scholar
• 19. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327(5969), 1135–1139 (2010).
  Medline CASGoogle Scholar
• 20. Najafov A, Luu HS, Mookhtiar AK et al. RIPK1 promotes energy sensing by the mTORC1 pathway. Mol. Cell 81(2), 370–385 e377 (2021). •• Describes the involvement of RIPK1 in celluar energy regulation.
  Medline CASGoogle Scholar
• 21. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat. Rev. Nephrol. 14(2), 121–137 (2018).
  Medline CASGoogle Scholar
• 22. Mcneal SI, Legolvan MP, Chung CS, Ayala A. The dual functions of receptor interacting protein 1 in fas-induced hepatocyte death during sepsis. Shock 35(5), 499–505 (2011). •• Describes the negative effects of RIPK1 inhibition on the survival of septic mice.
  Medline CASGoogle Scholar
• 23. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81(4), 513–523 (1995).
  Medline CASGoogle Scholar
• 24. Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat. Rev. Mol. Cell Biol. 14(11), 727–736 (2013).
  Medline CASGoogle Scholar
• 25. Xu D, Jin T, Zhu H et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 174(6), 1477–1491 e1419 (2018).
  Medline CASGoogle Scholar
• 26. Meng H, Liu Z, Li X et al. Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis. Proc. Natl Acad. Sci. USA 115(9), E2001–E2009 (2018).
  Medline CASGoogle Scholar
• 27. Li J, Mcquade T, Siemer AB et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150(2), 339–350 (2012).
  Medline CASGoogle Scholar
• 28. Park YH, Jeong MS, Park HH, Jang SB. Formation of the death domain complex between FADD and RIP1 proteins in vitro. Biochim. Biophys. Acta 1834(1), 292–300 (2013).
  Medline CASGoogle Scholar
• 29. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8(3), 297–303 (1998).
  Medline CASGoogle Scholar
• 30. Shan B, Pan H, Najafov A, Yuan J. Necroptosis in development and diseases. Genes Dev. 32(5-6), 327–340 (2018).
  Medline CASGoogle Scholar
• 31. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2), 181–190 (2003).
  Medline CASGoogle Scholar
• 32. Geng J, Ito Y, Shi L et al. Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. Nat. Commun. 8(1), 359 (2017).
  MedlineGoogle Scholar
• 33. Lafont E, Draber P, Rieser E et al. TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1 phosphorylation. Nat. Cell Biol. 20(12), 1389–1399 (2018).
  Medline CASGoogle Scholar
• 34. Dondelinger Y, Delanghe T, Priem D et al. Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation. Nat. Commun. 10(1), 1729 (2019).
  MedlineGoogle Scholar
• 35. Peltzer N, Darding M, Walczak H. Holding RIPK1 on the ubiquitin leash in TNFR1 signaling. Trends Cell Biol. 26(6), 445–461 (2016).
  Medline CASGoogle Scholar
• 36. Kroemer G, Galluzzi L, Vandenabeele P et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16(1), 3–11 (2009).
  Medline CASGoogle Scholar
• 37. Smith CC, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc. Drugs Ther. 21(4), 227–233 (2007).
  Medline CASGoogle Scholar
• 38. Li Y, Yang X, Ma C, Qiao J, Zhang C. Necroptosis contributes to the NMDA-induced excitotoxicity in rat's cultured cortical neurons. Neurosci. Lett. 447(2-3), 120–123 (2008).
  Medline CASGoogle Scholar
• 39. Han W, Li L, Qiu S et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol. Cancer Ther. 6(5), 1641–1649 (2007).
  Medline CASGoogle Scholar
• 40. Ito Y, Ofengeim D, Najafov A et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353(6299), 603–608 (2016).
  Medline CASGoogle Scholar
• 41. Ofengeim D, Mazzitelli S, Ito Y et al. RIPK1 mediates a disease-associated microglial response in Alzheimer's disease. Proc. Natl Acad. Sci. USA 114(41), E8788–E8797 (2017).
  Medline CASGoogle Scholar
• 42. Gunther C, Martini E, Wittkopf N et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 477(7364), 335–339 (2011).
  MedlineGoogle Scholar
• 43. O'donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol. 17(5), 418–424 (2007).
  MedlineGoogle Scholar
• 44. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22(2), 245–257 (2006).
  Medline CASGoogle Scholar
• 45. Li H, Kobayashi M, Blonska M, You Y, Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J. Biol. Chem. 281(19), 13636–13643 (2006).
  Medline CASGoogle Scholar
• 46. Bertrand MJ, Milutinovic S, Dickson KM et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30(6), 689–700 (2008).
  Medline CASGoogle Scholar
• 47. Gaither A, Porter D, Yao Y et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 67(24), 11493–11498 (2007).
  Medline CASGoogle Scholar
• 48. Petersen SL, Wang L, Yalcin-Chin A et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5), 445–456 (2007).
  Medline CASGoogle Scholar
• 49. Geserick P, Hupe M, Moulin M et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J. Cell Biol. 187(7), 1037–1054 (2009).
  Medline CASGoogle Scholar
• 50. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 267(25), 17971–17976 (1992).
  Medline CASGoogle Scholar
• 51. Wright A, Reiley WW, Chang M et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev. Cell 13(5), 705–716 (2007).
  Medline CASGoogle Scholar
• 52. Kanayama A, Seth RB, Sun L et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 15(4), 535–548 (2004).
  Medline CASGoogle Scholar
• 53. Legarda-Addison D, Hase H, O'donnell MA, Ting AT. NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling. Cell Death Differ. 16(9), 1279–1288 (2009).
  Medline CASGoogle Scholar
• 54. Arslan SC, Scheidereit C. The prevalence of TNFalpha-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay. PLOS ONE 6(10), e26069 (2011).
  Medline CASGoogle Scholar
• 55. Xia ZP, Sun L, Chen X et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461(7260), 114–119 (2009).
  Medline CASGoogle Scholar
• 56. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem. Pharmacol. 60(8), 1143–1151 (2000).
  Medline CASGoogle Scholar
• 57. Wertz IE, O'rourke KM, Zhou H et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signaling. Nature 430(7000), 694–699 (2004).
  Medline CASGoogle Scholar
• 58. Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signaling. EMBO J. 28(5), 513–522 (2009).
  Medline CASGoogle Scholar
• 59. Reiley WW, Jin W, Lee AJ et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204(6), 1475–1485 (2007).
  Medline CASGoogle Scholar
• 60. Efeyan A, Zoncu R, Chang S et al. Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. Nature 493(7434), 679–683 (2013).
  Medline CASGoogle Scholar
• 61. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412(2), 179–190 (2008).
  Medline CASGoogle Scholar
• 62. Seo SU, Woo SM, Lee HS, Kim SH, Min KJ, Kwon TK. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy. Oncogene 37(38), 5205–5220 (2018).
  Medline CASGoogle Scholar
• 63. Noda T. Regulation of autophagy through TORC1 and mTORC1. Biomolecules 7(3), 52 (2017).
  MedlineGoogle Scholar
• 64. Zhu SY, Yao RQ, Li YX et al. Lysosomal quality control of cell fate: a novel therapeutic target for human diseases. Cell Death Dis. 11(9), 817 (2020).
  Medline CASGoogle Scholar
• 65. Rickard JA, O'donnell JA, Evans JM et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157(5), 1175–1188 (2014).
  Medline CASGoogle Scholar
• 66. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5), 577–590 (2003).
  Medline CASGoogle Scholar
• 67. Cuchet-Lourenco D, Eletto D, Wu C et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science 361(6404), 810–813 (2018).
  Medline CASGoogle Scholar
• 68. Li Y, Fuhrer M, Bahrami E et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 116(3), 970–975 (2019).
  Medline CASGoogle Scholar
• 69. Furman D, Campisi J, Verdin E et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25(12), 1822–1832 (2019).
  Medline CASGoogle Scholar
• 70. Polykratis A, Hermance N, Zelic M et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J. Immunol. 193(4), 1539–1543 (2014).
  Medline CASGoogle Scholar
• 71. Patel S, Webster JD, Varfolomeev E et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 27(1), 161–175 (2020).
  Medline CASGoogle Scholar
• 72. Zelic M, Roderick JE, O'donnell JA et al. RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome. J. Clin. Invest. 128(5), 2064–2075 (2018).
  MedlineGoogle Scholar
• 73. Bolognese AC, Yang WL, Hansen LW et al. Inhibition of necroptosis attenuates lung injury and improves survival in neonatal sepsis. Surgery doi: 10.1016/j.surg.2018.02.017 (2018).
  MedlineGoogle Scholar
• 74. Liu Y, Xu Q, Wang Y et al. Necroptosis is active and contributes to intestinal injury in a piglet model with lipopolysaccharide challenge. Cell Death Dis. 12(1), 62 (2021).
  MedlineGoogle Scholar
• 75. Su Z, Dziedzic SA, Hu D et al. ABIN-1 heterozygosity sensitizes to innate immune response in both RIPK1-dependent and RIPK1-independent manner. Cell Death Differ. 26(6), 1077–1088 (2019).
  Medline CASGoogle Scholar
• 76. Najjar M, Saleh D, Zelic M et al. RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4. Immunity 45(1), 46–59 (2016).
  Medline CASGoogle Scholar
• 77. Lim SY, Davidson SM, Mocanu MM, Yellon DM, Smith CC. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc. Drugs Ther. 21(6), 467–469 (2007).
  Medline CASGoogle Scholar
• 78. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J. Pathol. 221(1), 3–12 (2010).
  Medline CASGoogle Scholar
• 79. Takahashi N, Vereecke L, Bertrand MJ et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513(7516), 95–99 (2014).
  Medline CASGoogle Scholar
• 80. Newton K, Dugger DL, Maltzman A et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 23(9), 1565–1576 (2016).
  Medline CASGoogle Scholar
• 81. Newton K, Dugger DL, Wickliffe KE et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 343(6177), 1357–1360 (2014).
  Medline CASGoogle Scholar
• 82. Xie T, Peng W, Liu Y et al. Structural basis of RIP1 inhibition by necrostatins. Structure 21(3), 493–499 (2013).
  Medline CASGoogle Scholar
• 83. Harris PA, Berger SB, Jeong JU et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J. Med. Chem. 60(4), 1247–1261 (2017).
  Medline CASGoogle Scholar
• 84. Harris PA, King BW, Bandyopadhyay D et al. DNA-encoded library screening identifies benzo[b] [1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J. Med. Chem. 59(5), 2163–2178 (2016).
  Medline CASGoogle Scholar
• 85. Berger SB, Harris P, Nagilla R et al. Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 1, 15009 (2015).
  Medline CASGoogle Scholar
• 86. Wang W, Marinis JM, Beal AM et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell 38(4), 585–590 (2020).
  Medline CASGoogle Scholar
• 87. Yoshikawa M, Saitoh M, Katoh T et al. Discovery of 7-oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure-kinetic relationships. J. Med. Chem. 61(6), 2384–2409 (2018).
  Medline CASGoogle Scholar
• 88. Hamilton GL, Chen H, Deshmukh G et al. Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group. Bioorg. Med. Chem. Lett. 29(12), 1497–1501 (2019).
  Medline CASGoogle Scholar
• 89. Weisel K, Scott NE, Tompson DJ et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol. Res. Perspect. 5(6), e00365 (2017).
  MedlineGoogle Scholar
• 90. Tompson DJ, Davies C, Scott NE et al. Comparison of the pharmacokinetics of RIPK1 inhibitor GSK2982772 in healthy Western and Japanese subjects. Eur. J. Drug Metab. Pharmacokinet. 46(1), 71–83 (2021).
  Medline CASGoogle Scholar
• 91. Yang X, Lu H, Xie H et al. Potent and selective RIPK1 inhibitors targeting dual-pockets for the treatment of systemic inflammatory response syndrome and sepsis. Angew Chem. Int. Ed. Engl. 61(5), e202114922 (2022). •• Describes animal experiments with RIPK1 inhibitors for the treatment of sepsis.
  Medline CASGoogle Scholar
• 92. Weisel K, Berger S, Papp K et al. Response to inhibition of receptor-interacting protein kinase 1 (RIPK1) in active plaque psoriasis: a randomized placebo-controlled study. Clin. Pharmacol. Ther. 108(4), 808–816 (2020).
  Medline CASGoogle Scholar
• 93. Weisel K, Scott N, Berger S et al. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol. 8(1), e000680 (2021).
  MedlineGoogle Scholar
• 94. Weisel K, Berger S, Thorn K et al. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. Arthritis Res. Ther. 23(1), 85 (2021).
  Medline CASGoogle Scholar
• 95. Grievink HW, Heuberger J, Huang F et al. DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clin. Pharmacol. Ther. 107(2), 406–414 (2020).
  Medline CASGoogle Scholar
• 96. CORRIGENDUM: DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clin. Pharmacol. Ther. 109(6), 1678–1679 (2021).
  MedlineGoogle Scholar
• 97. Denali Therapeutics. Denali Therapeutics announces that its partner Sanofi has commenced dosing of DNL758 in a phase 1 study (2019). www.globenewswire.com/news release /2019/08 / 05/1896875/0/en/Denali-Therapeutics-Announces- That-Its- Partner-Sanofihas-Commenced- Dosing-of- DNL758-in- a-Phase-1-Study.html
  Google Scholar
• 98. US National Library of Medicine. (2018). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03757351
  Google Scholar
• 99. US National Library of Medicine. (2018). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03757325
  Google Scholar
• 100. US National Library of Medicine. (2018). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03681951
  Google Scholar
• 101. Rigel Pharmaceuticals. Rigel Pharmaceuticals provides business update prior to investor & analyst call (2019). https://ir.rigel.com/news-events/press- releases/detail/270/rigel-pharmaceuticals-provides-businessupdate-prior-to
  Google Scholar
• 102. GlaxoSmithKline. Our pipeline: pipeline changes (2019). www.gsk.com/en-gb/research-anddevelopment/our-pipeline/#pipeline-changes
  Google Scholar
• 103. Ofengeim D, Ito Y, Najafov A et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 10(11), 1836–1849 (2015).
  Medline CASGoogle Scholar
• 104. Zhu K, Liang W, Ma Z et al. Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis. 9(5), 500 (2018).
  MedlineGoogle Scholar
• 105. Wang B, Li J, Gao HM et al. Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study. Oncotarget 8(48), 84066–84073 (2017).
  MedlineGoogle Scholar
• 106. Mallarpu CS, Ponnana M, Prasad S et al. Distinct cell death markers identified in critical care patient survivors diagnosed with sepsis. Immunol. Lett. 231, 1–10 (2021).
  Medline CASGoogle Scholar
• 107. Yoo H, Im Y, Ko RE, Lee JY, Park J, Jeon K. Association of plasma level of high-mobility group box-1 with necroptosis and sepsis outcomes. Sci. Rep. 11(1), 9512 (2021).
  Medline CASGoogle Scholar
• 108. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94(2), 331–335 (1983).
  Medline CASGoogle Scholar
• 109. Kuzmich NN, Sivak KV, Chubarev VN, Porozov YB, Savateeva-Lyubimova TN, Peri F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel) 5(4), 34 (2017).
  MedlineGoogle Scholar
• 110. Berger SB, Kasparcova V, Hoffman S et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J. Immunol. 192(12), 5476–5480 (2014).
  Medline CASGoogle Scholar
• 111. Martens S, Hofmans S, Declercq W, Augustyns K, Vandenabeele P. Inhibitors targeting RIPK1/RIPK3: old and new drugs. Trends Pharmacol. Sci. 41(3), 209–224 (2020).
  Medline CASGoogle Scholar
• 112. Speir M, Djajawi TM, Conos SA, Tye H, Lawlor KE. Targeting RIP kinases in chronic inflammatory disease. Biomolecules 11(5), 646 (2021).
  Medline CASGoogle Scholar
• 113. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 39(5), 517–528 (2017).
  Medline CASGoogle Scholar
• 114. Ince C, Mayeux PR, Nguyen T et al. The endothelium in sepsis. Shock 45(3), 259–270 (2016). • Describes the role of endothelial cells in sepsis.
  Medline CASGoogle Scholar